Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience.

Innocenti I, Morelli F, Autore F, Piciocchi A, Frustaci A, Mauro FR, Schiattone L, Trentin L, Del Poeta G, Reda G, Rigolin GM, Ibatici A, Ciolli S, Coscia M, Sportoletti P, Murru R, Levato L, Gentile M, D'Arena G, Efremov DG, Tedeschi A, Scarfò L, Cuneo A, Foà R, Laurenti L.

Br J Haematol. 2019 Jul 31. doi: 10.1111/bjh.16123. [Epub ahead of print] No abstract available.

PMID:
31364153
2.

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.

Fava C, Rege-Cambrin G, Dogliotti I, Cerrano M, Berchialla P, Dragani M, Rosti G, Castagnetti F, Gugliotta G, Martino B, Gambacorti-Passerini C, Abruzzese E, Elena C, Pregno P, Gozzini A, Capodanno I, Bergamaschi M, Crugnola M, Bocchia M, Galimberti S, Rapezzi D, Iurlo A, Cattaneo D, Latagliata R, Breccia M, Cedrone M, Santoro M, Annunziata M, Levato L, Stagno F, Cavazzini F, Sgherza N, Giai V, Luciano L, Russo S, Musto P, Caocci G, Sorà F, Iuliano F, Lunghi F, Specchia G, Pane F, Ferrero D, Baccarani M, Saglio G.

Haematologica. 2019 Aug;104(8):1589-1596. doi: 10.3324/haematol.2018.205054. Epub 2019 Feb 28.

3.

The magnitude of improvement in progression-free survival with targeted therapy in relapsed/refractory chronic lymphocytic leukemia based on prognostic risk category: a systematic review and meta-analysis.

Molica S, Giannarelli D, Mirabelli R, Levato L, Shanafelt TD.

Leuk Lymphoma. 2019 Jul;60(7):1644-1649. doi: 10.1080/10428194.2018.1543882. Epub 2018 Dec 5.

PMID:
30516079
4.

A simple score based on geriatric assessment predicts survival in elderly newly diagnosed chronic lymphocytic leukemia patients.

Molica S, Giannarelli D, Levato L, Mirabelli R, Levato D, Lentini M, Piro E.

Leuk Lymphoma. 2019 Mar;60(3):845-847. doi: 10.1080/10428194.2018.1508674. Epub 2018 Oct 2. No abstract available.

PMID:
30277125
5.

Parent Training for Feeding Problems in Children With Autism Spectrum Disorder: Initial Randomized Trial.

Johnson CR, Brown K, Hyman SL, Brooks MM, Aponte C, Levato L, Schmidt B, Evans V, Huo Z, Bendixen R, Eng H, Sax T, Smith T.

J Pediatr Psychol. 2019 Mar 1;44(2):164-175. doi: 10.1093/jpepsy/jsy063.

PMID:
30101320
6.

Chronic lymphocytic leukemia international prognostic index (CLL-IPI) in patients receiving chemoimmuno or targeted therapy: a systematic review and meta-analysis.

Molica S, Giannarelli D, Mirabelli R, Levato L, Shanafelt TD.

Ann Hematol. 2018 Oct;97(10):2005-2008. doi: 10.1007/s00277-018-3350-5. Epub 2018 May 8. Review. No abstract available.

PMID:
29740683
7.

Sustained Erythroid Response in a Patient with Myelofibrosis Receiving Concomitant Treatment with Ruxolitinib and Deferasirox.

Piro E, Lentini M, Levato L, Russo A, Molica S.

Chemotherapy. 2018 Apr 25;63(2):107-110. doi: 10.1159/000486822. [Epub ahead of print]

PMID:
29694973
8.

Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.

Efficace F, Castagnetti F, Martino B, Breccia M, D'Adda M, Angelucci E, Stagno F, Cottone F, Malato A, Trabacchi E, Capalbo SF, Gobbi M, Visani G, Salvucci M, Capodanno I, Tosi P, Tiribelli M, Scortechini AR, Levato L, Maino E, Binotto G, Gugliotta G, Vignetti M, Baccarani M, Rosti G.

Cancer. 2018 May 15;124(10):2228-2237. doi: 10.1002/cncr.31323. Epub 2018 Mar 2.

9.

Feasibility and safety of therapy with ibrutinib after antiviral control of hepatitis B virus (HBV) reactivation in chronic lymphocytic leukemia patients.

Molica S, Levato L, Mirabelli R, Tedeschi A, Lentini M.

Leuk Lymphoma. 2018 Nov;59(11):2734-2736. doi: 10.1080/10428194.2018.1436175. Epub 2018 Feb 21. No abstract available.

PMID:
29465275
10.

Broken bridges-new school transitions for students with autism spectrum disorder: A systematic review on difficulties and strategies for success.

Nuske HJ, McGhee Hassrick E, Bronstein B, Hauptman L, Aponte C, Levato L, Stahmer A, Mandell DS, Mundy P, Kasari C, Smith T.

Autism. 2019 Feb;23(2):306-325. doi: 10.1177/1362361318754529. Epub 2018 Feb 19.

PMID:
29458258
11.

Rituximab in the management of acute lymphoblastic leukemia.

Levato L, Molica S.

Expert Opin Biol Ther. 2018 Feb;18(2):221-226. doi: 10.1080/14712598.2018.1425389. Epub 2018 Jan 17.

PMID:
29310477
12.

A pilot investigation of an iOS-based app for toilet training children with autism spectrum disorder.

Mruzek DW, McAleavey S, Loring WA, Butter E, Smith T, McDonnell E, Levato L, Aponte C, Travis RP, Aiello RE, Taylor CM, Wilkins JW, Corbett-Dick P, Finkelstein DM, York AM, Zanibbi K.

Autism. 2019 Feb;23(2):359-370. doi: 10.1177/1362361317741741. Epub 2017 Dec 7.

PMID:
29212345
13.

Chronic lymphocytic leukemia international prognostic index: a systematic review and meta-analysis.

Molica S, Giannarelli D, Mirabelli R, Levato L, Kay NE, Shanafelt TD.

Blood. 2018 Jan 18;131(3):365-368. doi: 10.1182/blood-2017-09-806034. Epub 2017 Oct 30. No abstract available.

14.

Teaching Parents Behavioral Strategies for Autism Spectrum Disorder (ASD): Effects on Stress, Strain, and Competence.

Iadarola S, Levato L, Harrison B, Smith T, Lecavalier L, Johnson C, Swiezy N, Bearss K, Scahill L.

J Autism Dev Disord. 2018 Apr;48(4):1031-1040. doi: 10.1007/s10803-017-3339-2.

PMID:
28988339
15.

Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia.

Gugliotta G, Castagnetti F, Breccia M, Albano F, Iurlo A, Intermesoli T, Abruzzese E, Levato L, D'Adda M, Pregno P, Cavazzini F, Stagno F, Martino B, La Barba G, Sorà F, Tiribelli M, Bigazzi C, Binotto G, Bonifacio M, Caracciolo C, Soverini S, Foà R, Cavo M, Martinelli G, Pane F, Saglio G, Baccarani M, Rosti G; Gruppo Italiano Malattie Ematologiche dell’Adulto - Chronic Myeloid Leukemia Working Party.

Haematologica. 2017 Sep;102(9):1530-1536. doi: 10.3324/haematol.2017.169532. Epub 2017 Jun 1.

16.

The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.

Castagnetti F, Gugliotta G, Breccia M, Iurlo A, Levato L, Albano F, Vigneri P, Abruzzese E, Rossi G, Rupoli S, Cavazzini F, Martino B, Orlandi E, Pregno P, Annunziata M, Usala E, Tiribelli M, Sica S, Bonifacio M, Fava C, Gherlinzoni F, Bocchia M, Soverini S, Bochicchio MT, Cavo M, Giovanni M, Saglio G, Pane F, Baccarani M, Rosti G; GIMEMA CML Working Party.

Am J Hematol. 2017 Aug;92(8):797-805. doi: 10.1002/ajh.24774. Epub 2017 May 30.

17.

Reliability of six prognostic models to predict time-to-first-treatment in patients with chronic lymphocytic leukaemia in early phase.

Molica S, Giannarelli D, Mirabelli R, Levato L, Gentile M, Morabito F, Montserrat E.

Am J Hematol. 2017 Jun;92(6):E91-E93. doi: 10.1002/ajh.24707. Epub 2017 Mar 24. No abstract available.

18.

Assessing time to first treatment in early chronic lymphocytic leukemia (CLL): a comparative performance analysis of five prognostic models with inclusion of CLL-international prognostic index (CLL-IPI).

Molica S, Giannarelli D, Levato L, Mirabelli R, Gentile M, Morabito F.

Leuk Lymphoma. 2017 Jul;58(7):1736-1739. doi: 10.1080/10428194.2016.1257791. Epub 2016 Nov 22. No abstract available.

PMID:
27875912
19.

The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients.

Molica S, Shanafelt TD, Giannarelli D, Gentile M, Mirabelli R, Cutrona G, Levato L, Di Renzo N, Di Raimondo F, Musolino C, Angrilli F, Famà A, Recchia AG, Chaffee KG, Neri A, Kay NE, Ferrarini M, Morabito F.

Am J Hematol. 2016 Nov;91(11):1090-1095. doi: 10.1002/ajh.24493. Epub 2016 Aug 8.

20.

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients.

Castagnetti F, Breccia M, Gugliotta G, Martino B, D'Adda M, Stagno F, Carella AM, Avanzini P, Tiribelli M, Trabacchi E, Visani G, Gobbi M, Salvucci M, Levato L, Binotto G, Capalbo SF, Bochicchio MT, Soverini S, Cavo M, Martinelli G, Alimena G, Pane F, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party.

Haematologica. 2016 Oct;101(10):1200-1207. Epub 2016 Jul 28.

21.

Effect of Parent Training on Adaptive Behavior in Children With Autism Spectrum Disorder and Disruptive Behavior: Results of a Randomized Trial.

Scahill L, Bearss K, Lecavalier L, Smith T, Swiezy N, Aman MG, Sukhodolsky DG, McCracken C, Minshawi N, Turner K, Levato L, Saulnier C, Dziura J, Johnson C.

J Am Acad Child Adolesc Psychiatry. 2016 Jul;55(7):602-609.e3. doi: 10.1016/j.jaac.2016.05.001. Epub 2016 May 7.

22.

Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials.

Gentile M, Zirlik K, Ciolli S, Mauro FR, Di Renzo N, Mastrullo L, Angrilli F, Molica S, Tripepi G, Giordano A, Di Raimondo F, Selleri C, Coscia M, Musso M, Orsucci L, Mannina D, Rago A, Giannotta A, Ferrara F, Herishanu Y, Shvidel L, Tadmor T, Scortechini I, Ilariucci F, Murru R, Guarini A, Musuraca G, Mineo G, Vincelli I, Arcari A, Tarantini G, Caparrotti G, Chiarenza A, Levato L, Villa MR, De Paolis MR, Zinzani PL, Polliack A, Morabito F.

Eur J Cancer. 2016 Jun;60:154-65. doi: 10.1016/j.ejca.2016.03.069. Epub 2016 Apr 27.

PMID:
27127905
23.

Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia.

Gugliotta G, Castagnetti F, Breccia M, Gozzini A, Usala E, Carella AM, Rege-Cambrin G, Martino B, Abruzzese E, Albano F, Stagno F, Luciano L, D'Adda M, Bocchia M, Cavazzini F, Tiribelli M, Lunghi M, Pia Falcone A, Musolino C, Levato L, Venturi C, Soverini S, Cavo M, Alimena G, Pane F, Martinelli G, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party.

Am J Hematol. 2016 Jun;91(6):617-22. doi: 10.1002/ajh.24362. Epub 2016 Apr 24.

24.

Use of urine alarms in toilet training children with intellectual and developmental disabilities: A review.

Levato LE, Aponte CA, Wilkins J, Travis R, Aiello R, Zanibbi K, Loring WA, Butter E, Smith T, Mruzek DW.

Res Dev Disabil. 2016 Jun-Jul;53-54:232-41. doi: 10.1016/j.ridd.2016.02.007. Epub 2016 Mar 2. Review.

PMID:
26942703
25.

A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients.

Gentile M, Shanafelt TD, Cutrona G, Molica S, Tripepi G, Alvarez I, Mauro FR, Di Renzo N, Di Raimondo F, Vincelli I, Todoerti K, Matis S, Musolino C, Fabris S, Vigna E, Levato L, Zupo S, Angrilli F, Consoli U, Festini G, Longo G, Cortelezzi A, Arcari A, Federico M, Mannina D, Recchia AG, Neri A, Kay NE, Ferrarini M, Morabito F.

Leukemia. 2016 Jun;30(6):1440-3. doi: 10.1038/leu.2015.333. Epub 2015 Dec 9. No abstract available.

PMID:
26648537
26.

Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.

Handen BL, Aman MG, Arnold LE, Hyman SL, Tumuluru RV, Lecavalier L, Corbett-Dick P, Pan X, Hollway JA, Buchan-Page KA, Silverman LB, Brown NV, Rice RR Jr, Hellings J, Mruzek DW, McAuliffe-Bellin S, Hurt EA, Ryan MM, Levato L, Smith T.

J Am Acad Child Adolesc Psychiatry. 2015 Nov;54(11):905-15. doi: 10.1016/j.jaac.2015.08.013. Epub 2015 Sep 3.

27.

Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature.

Molica S, Levato L, Mirabelli R.

Leuk Lymphoma. 2016;57(3):735-7. doi: 10.3109/10428194.2015.1071489. Epub 2015 Oct 12. Review. No abstract available.

PMID:
26337717
28.

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia.

Gugliotta G, Castagnetti F, Breccia M, Levato L, D'Adda M, Stagno F, Tiribelli M, Salvucci M, Fava C, Martino B, Cedrone M, Bocchia M, Trabacchi E, Cavazzini F, Usala E, Russo Rossi A, Bochicchio MT, Soverini S, Alimena G, Cavo M, Pane F, Martinelli G, Saglio G, Baccarani M, Rosti G; GIMEMA CML Working Party.

Haematologica. 2015 Sep;100(9):1146-50. doi: 10.3324/haematol.2015.129221. Epub 2015 Jun 25.

29.

Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myleoid Leukemia: Comparison with FISH and PCR Techniques.

Recchia AG, Caruso N, Bossio S, Pellicanò M, De Stefano L, Franzese S, Palummo A, Abbadessa V, Lucia E, Gentile M, Vigna E, Caracciolo C, Agostino A, Galimberti S, Levato L, Stagno F, Molica S, Martino B, Vigneri P, Di Raimondo F, Morabito F.

PLoS One. 2015 Jun 25;10(6):e0130360. doi: 10.1371/journal.pone.0130360. eCollection 2015.

30.

Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.

Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F, Abruzzese E, Martino B, Levato L, Intermesoli T, Pregno P, Rossi G, Gherlinzoni F, Leoni P, Cavazzini F, Venturi C, Soverini S, Testoni N, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party.

Leukemia. 2015 Sep;29(9):1823-31. doi: 10.1038/leu.2015.152. Epub 2015 Jun 19.

PMID:
26088952
31.

Unavailability of thymidine kinase does not preclude the use of German comprehensive prognostic index: results of an external validation analysis in early chronic lymphocytic leukemia and comparison with MD Anderson Cancer Center model.

Molica S, Giannarelli D, Mirabelli R, Levato L, Russo A, Linardi M, Gentile M, Morabito F.

Eur J Haematol. 2016 Jan;96(1):72-7. doi: 10.1111/ejh.12550. Epub 2015 Apr 18.

PMID:
25819739
32.

Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study.

Gentile M, Cutrona G, Molica S, Ilariucci F, Mauro FR, Di Renzo N, Di Raimondo F, Vincelli I, Todoerti K, Matis S, Musolino C, Fabris S, Lionetti M, Levato L, Zupo S, Angrilli F, Consoli U, Festini G, Longo G, Cortelezzi A, Musto P, Federico M, Neri A, Ferrarini M, Morabito F.

Eur J Haematol. 2016 Jan;96(1):36-45. doi: 10.1111/ejh.12545. Epub 2015 Mar 31.

PMID:
25753656
33.

Do biologic parameters affect the time to first treatment of clinical monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Rai stage 0? Results of a prospective analysis.

Molica S, Giannarelli D, Levato L, Gentile M, Mirabelli R, Morabito F.

Clin Lymphoma Myeloma Leuk. 2015 Mar;15(3):e55-60. doi: 10.1016/j.clml.2014.09.003. Epub 2014 Sep 28.

PMID:
25445470
34.

Differences among young adults, adults and elderly chronic myeloid leukemia patients.

Castagnetti F, Gugliotta G, Baccarani M, Breccia M, Specchia G, Levato L, Abruzzese E, Rossi G, Iurlo A, Martino B, Pregno P, Stagno F, Cuneo A, Bonifacio M, Gobbi M, Russo D, Gozzini A, Tiribelli M, de Vivo A, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G; GIMEMA CML Working Party.

Ann Oncol. 2015 Jan;26(1):185-92. doi: 10.1093/annonc/mdu490. Epub 2014 Oct 30.

PMID:
25361995
35.

Changes in the incidence, pattern of presentation and clinical outcome of early chronic lymphocytic leukemia patients using the 2008 International Workshop on CLL guidelines.

Molica S, Giannarelli D, Mirabelli R, Levato L, Gentile M, Lentini M, Morabito F.

Expert Rev Hematol. 2014 Oct;7(5):691-5. doi: 10.1586/17474086.2014.954542. Epub 2014 Aug 31.

PMID:
25174547
36.

A prognostic algorithm including a modified version of MD Anderson Cancer Center (MDACC) score predicts time to first treatment of patients with clinical monoclonal lymphocytosis (cMBL)/Rai stage 0 chronic lymphocytic leukemia (CLL).

Molica S, Giannarelli D, Levato L, Mirabelli R, Gentile M, Lentini M, Morabito F.

Int J Hematol. 2014 Sep;100(3):290-5. doi: 10.1007/s12185-014-1634-7. Epub 2014 Jul 27.

PMID:
25064370
37.

A review of atomoxetine effects in young people with developmental disabilities.

Aman MG, Smith T, Arnold LE, Corbett-Dick P, Tumuluru R, Hollway JA, Hyman SL, Mendoza-Burcham M, Pan X, Mruzek DW, Lecavalier L, Levato L, Silverman LB, Handen B.

Res Dev Disabil. 2014 Jun;35(6):1412-24. doi: 10.1016/j.ridd.2014.03.006. Epub 2014 Apr 16. Review.

38.

Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study.

Gentile M, Cutrona G, Mosca L, Matis S, Fabris S, Lionetti M, Ilariucci F, Zupo S, Musolino C, Levato L, Molica S, Di Raimondo F, Vincelli I, Di Rienzo N, Pesce EA, Angrilli F, Federico M, Neri A, Ferrarini M, Morabito F.

Am J Hematol. 2014 Jul;89(7):743-50. doi: 10.1002/ajh.23729. Epub 2014 Apr 18.

39.

Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study.

Levato L, Cantaffa R, Kropp MG, Magro D, Piro E, Molica S.

Eur J Haematol. 2013 Jun;90(6):531-2. doi: 10.1111/ejh.12096. Epub 2013 Mar 18. No abstract available.

PMID:
23506097
40.

Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib.

Kim TD, Rea D, Schwarz M, Grille P, Nicolini FE, Rosti G, Levato L, Giles FJ, Dombret H, Mirault T, Labussière H, Lindhorst R, Haverkamp W, Buschmann I, Dörken B, le Coutre PD.

Leukemia. 2013 Jun;27(6):1316-21. doi: 10.1038/leu.2013.70. Epub 2013 Mar 5.

PMID:
23459449
41.

Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib.

Efficace F, Baccarani M, Breccia M, Cottone F, Alimena G, Deliliers GL, Baratè C, Specchia G, Di Lorenzo R, Luciano L, Turri D, Martino B, Stagno F, Dabusti M, Bergamaschi M, Leoni P, Simula MP, Levato L, Fava C, Veneri D, Sica S, Rambaldi A, Rosti G, Vignetti M, Mandelli F.

Leukemia. 2013 Jul;27(7):1511-9. doi: 10.1038/leu.2013.51. Epub 2013 Feb 18.

PMID:
23417029
42.

Vitamin D insufficiency predicts time to first treatment (TFT) in early chronic lymphocytic leukemia (CLL).

Molica S, Digiesi G, Antenucci A, Levato L, Mirabelli R, Molica M, Gentile M, Giannarelli D, Sperduti I, Morabito F, Conti L.

Leuk Res. 2012 Apr;36(4):443-7. doi: 10.1016/j.leukres.2011.10.004. Epub 2011 Nov 1.

PMID:
22047708
43.

Reversal of leukostasis-related pulmonary distress syndrome after leukapheresis and low-dose chemotherapy in acute myeloid leukemia.

Piro E, Carillio G, Levato L, Kropp M, Molica S.

J Clin Oncol. 2011 Sep 10;29(26):e725-6. doi: 10.1200/JCO.2011.36.2756. Epub 2011 Aug 8. No abstract available.

PMID:
21825265
44.

Clinical relevance and treatment of nonautoimmune anemia in chronic lymphocytic leukemia.

Molica S, Mirabelli R, Molica M, Levato L, Mauro FR, Foà R.

Cancer Manag Res. 2011;3:211-7. doi: 10.2147/CMR.S17470. Epub 2011 Jun 1.

45.

Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population.

Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F, Deliliers GL, Baratè C, Rossi AR, Fioritoni G, Luciano L, Turri D, Martino B, Di Raimondo F, Dabusti M, Bergamaschi M, Leoni P, Simula MP, Levato L, Ulisciani S, Veneri D, Sica S, Rambaldi A, Vignetti M, Mandelli F; GIMEMA.

Blood. 2011 Oct 27;118(17):4554-60. doi: 10.1182/blood-2011-04-347575. Epub 2011 Jul 12.

46.

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia.

Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G, Capucci A, Cedrone M, Fava C, Intermesoli T, Cambrin GR, Stagno F, Tiribelli M, Amabile M, Luatti S, Poerio A, Soverini S, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G, Baccarani M; GIMEMA CML Working Party.

Blood. 2009 Dec 3;114(24):4933-8. doi: 10.1182/blood-2009-07-232595. Epub 2009 Oct 12.

47.

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study.

Baccarani M, Rosti G, Castagnetti F, Haznedaroglu I, Porkka K, Abruzzese E, Alimena G, Ehrencrona H, Hjorth-Hansen H, Kairisto V, Levato L, Martinelli G, Nagler A, Lanng Nielsen J, Ozbek U, Palandri F, Palmieri F, Pane F, Rege-Cambrin G, Russo D, Specchia G, Testoni N, Weiss-Bjerrum O, Saglio G, Simonsson B.

Blood. 2009 May 7;113(19):4497-504. doi: 10.1182/blood-2008-12-191254. Epub 2009 Mar 4.

48.

The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up.

Palandri F, Castagnetti F, Alimena G, Testoni N, Breccia M, Luatti S, Rege-Cambrin G, Stagno F, Specchia G, Martino B, Levato L, Merante S, Liberati AM, Pane F, Saglio G, Alberti D, Martinelli G, Baccarani M, Rosti G.

Haematologica. 2009 Feb;94(2):205-12. doi: 10.3324/haematol.13529. Epub 2009 Jan 14.

49.

Clinico-biological implications of increased serum levels of interleukin-8 in B-cell chronic lymphocytic leukemia.

Molica S, Vitelli G, Levato D, Levato L, Dattilo A, Gandolfo GM.

Haematologica. 1999 Mar;84(3):208-11.

50.

Supplemental Content

Loading ...
Support Center